Altesa BioSciences Shares Phase 2 Vapendavir Data at ASM 2026
05 Jun 2026 //
PR NEWSWIRE
Altesa Bio Appoints Board Member and SVP of Clinical Development
02 Jun 2026 //
PR NEWSWIRE
Altesa BioSciences: Positive Phase 2 Data for Vapendavir
19 May 2026 //
PR NEWSWIRE
Altesa BioSciences` Vapendavir Targets All 3 Rhinovirus Species
12 May 2026 //
PR NEWSWIRE
Altesa Enrolls First Patient in Phase 2b CARDINAL COPD Trial
05 May 2026 //
PR NEWSWIRE
Altesa BioSciences Delivers Oral Presentation at ATS 2026
30 Apr 2026 //
PR NEWSWIRE
Vapendavir Selected For ICAR 2026 Oral Presentation
19 Mar 2026 //
PR NEWSWIRE
Altesa Bio Shows Vapendavir Benefits In Rhinovirus COPD Study
28 Sep 2025 //
PR NEWSWIRE

Market Place
Sourcing Support